A Novel CAR-T Cell Product Targeting CD74 Is an Effective Therapeutic Approach in Preclinical Mantle Cell Lymphoma Models

Investigators explored whether targeting CD74 using a CAR-T cell would provide potent and durable anti-mantle cell lymphoma activity. They engineered a second generation anti-CD74 CAR with 4-1BB and CD3ζ signaling domains.